Paris, France and Cambridge, MA, USA – May 19, 2016
Enterome Bioscience SA (“Enterome”), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce that it has opened a new office in Cambridge, MA to support its operations and corporate development activities in the US.
The office is located at Kendall Square, the heart of Boston’s booming biotechnology industry, well-known as the global hub for transforming scientific insights into new drugs. The new office brings Enterome closer to its existing partners in the US and provides opportunities to reinforce and extend its scientific expertise and network to develop its business further.
Rodolphe Clerval, Enterome’s Chief Business Officer, will head up the US office, and expects to expand the operation over the coming years.
Mr Clerval said: “Enterome has made great progress leveraging its expertise to unlock the microbiome and identify exciting opportunities to improve the treatment of serious diseases. We have established several partnerships and strong relationships in the US with companies and clinicians at leading research institutions. By starting operations in one of the most vibrant life sciences hubs in the world, we can leverage on these relationships and advance the development of Enterome.”
Enterome currently has partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.